The small dilutions are required to improve recovery in serum/plasma samples due to a strong matrix effect. Improved recovery was observed when using 1:6 diluted samples compared to neat or lower dilution. It may seem counter-intuitive, but the dilution reduces the matrix effect and improves sample recovery and detectability.
HCCBP1MAG-58K
MILLIPLEX® Human Circulating Cancer Biomarker Magnetic Bead Panel - Cancer Multiplex Assay
Circulating Cancer Biomarker Bead-Based Multiplex Assays using the Luminex technology enables the simultaneous analysis of multiple oncology biomarkers in various tumor types in human serum, plasma and cell culture samples.
別名:
human cancer biomarker immunoassay panel, luminex human circulating cancer biomarkers multiplex assay, millipore human circulating cancer biomarkers multiplex kit
ログイン組織・契約価格を表示する
すべての画像(4)
About This Item
UNSPSCコード:
12161503
eCl@ss:
32161000
NACRES:
NA.84
To order a Milliplex® kit, please search for your analyte of interest.
おすすめの製品
品質水準
交差性
human
メーカー／製品名
Milliplex®
assay range
accuracy: 35-108%
standard curve range: 0.09-67 mU/mL
(β-HCG)
standard curve range: 0.7-500 pg/mL
(IL-6)
standard curve range: 1.3-1000 pg/mL
(IL-8, TNFα)
standard curve range: 2.7-2000 pg/mL
(TRAIL, TGF-α)
standard curve range: 6.9-5000 pg/mL
(SCF)
テクニック
multiplexing: suitable
検出方法
fluorometric (Luminex xMAP)
輸送温度
wet ice
詳細
Circulating cancer biomarkers give insight beyond intracellular oncogenesis and into how the body responds to the presence of a tumor, the dysregulation of homeostasis, and the relationship between a tumor and its environment. Multianalyte panels have become essential tools that enable researchers to measure cancer biomarkers simultaneously, teasing out these relationships and applying them to understand tumor biology.
MILLIPLEX® Circulating Cancer Biomarker Panel 1 is a 25-plex kit that can be used for the simultaneous quantification of any or all of the following analytes in serum, plasma and tissue/cell lysate and culture supernatant samples: AFP, CA125, CA15-3, CA19-9, CEA, CYFRA21-1, sFas, sFasL, FGF2, β-HCG, HE4, HGF, IL-6, IL-8, Leptin, MIF, Osteopontin, Prolactin, PSA (free), PSA (total), SCF, TGFα, TNFα, TRAIL and VEGF. Note that certain biomarkers are tumor specific, such as PSA, while others, such as IL-8, have been detected in many cancers. PSA (free) and PSA (total) cannot be plexed together. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.
The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.
Panel Type: Circulating Cancer
MILLIPLEX® Circulating Cancer Biomarker Panel 1 is a 25-plex kit that can be used for the simultaneous quantification of any or all of the following analytes in serum, plasma and tissue/cell lysate and culture supernatant samples: AFP, CA125, CA15-3, CA19-9, CEA, CYFRA21-1, sFas, sFasL, FGF2, β-HCG, HE4, HGF, IL-6, IL-8, Leptin, MIF, Osteopontin, Prolactin, PSA (free), PSA (total), SCF, TGFα, TNFα, TRAIL and VEGF. Note that certain biomarkers are tumor specific, such as PSA, while others, such as IL-8, have been detected in many cancers. PSA (free) and PSA (total) cannot be plexed together. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.
The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.
Panel Type: Circulating Cancer
特異性
Cross Reactivty
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
アプリケーション
- Analytes: α-Fetoprotein (AFP), CA125, CA15-3, CA19-9, CEA, CYFRA21-1, sFas (TNFRSF6), sFasL, FGF-2 (FGF-basic), β-HCG (HCGβ), HE4, HGF, IL-6, IL-8 (CXCL8), Leptin, MIF, Osteopontin (OPN), Prolactin, PSA (free)*, PSA (total)*, SCF, TGFα, TNFα, TRAIL (TNFSF10), VEGF.
- Note: Total PSA and Free PSA cannot be plexed together
- Recommended Sample Type: Human serum, plasma or tissue/cell culture supernatants or lysates
- Recommended Sample Dilution: 25 μL per well of 1:6 diluted plasma or serum, or 25 μL cell culture psaesaa sample undiluted or diluted in appropriate control medium
- Assay Run Time: Overnight (16-18 hr) at 2-8°C
- Research Category: Cancer
特徴および利点
Design your multiplex kit by choosing available analytes within this panel.
包装
Everything you need in a single kit.
構成
Human Circulating Cancer Biomarker Panel 1 Standard (HCC-8058)
Human Circulating Cancer Biomarker Panel 1 Quality Controls 1 and 2 (HCC-6058)
Serum Matrix (HCP-SM)
Note: Contains 0.08% Sodium Azide
Set of one 96-Well Plate with 2 Sealers (MAG-PLATE)
Assay Buffer (L-AB)
Note: Contains 0.08% Sodium Azide
10X Wash Buffer (L-WB)
Note: Contains 0.05% Proclin
Human Circulating Cancer Biomarker Panel 1 Detection Antibodies (HCC-1058 or HCC-1058-2)
Streptavidin-Phycoerythrin (L-SAPE 4)
Bead Diluent (LBD-4)
Human Circulating Cancer Biomarker Panel 1 Quality Controls 1 and 2 (HCC-6058)
Serum Matrix (HCP-SM)
Note: Contains 0.08% Sodium Azide
Set of one 96-Well Plate with 2 Sealers (MAG-PLATE)
Assay Buffer (L-AB)
Note: Contains 0.08% Sodium Azide
10X Wash Buffer (L-WB)
Note: Contains 0.05% Proclin
Human Circulating Cancer Biomarker Panel 1 Detection Antibodies (HCC-1058 or HCC-1058-2)
Streptavidin-Phycoerythrin (L-SAPE 4)
Bead Diluent (LBD-4)
保管および安定性
Recommended storage for kit components is 2 - 8°C.
その他情報
Please note: Total PSA and Free PSA cannot be plexed together.
Sensitivity: Refer to kit protocol for sensitivities of individual biomarkers.
法的情報
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
シグナルワード
Danger
危険有害性の分類
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
ターゲットの組織
Respiratory Tract
保管分類コード
10 - Combustible liquids
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
毒物及び劇物取締法
キットコンポーネントの情報を参照してください
PRTR
キットコンポーネントの情報を参照してください
消防法
キットコンポーネントの情報を参照してください
労働安全衛生法名称等を表示すべき危険物及び有害物
キットコンポーネントの情報を参照してください
労働安全衛生法名称等を通知すべき危険物及び有害物
キットコンポーネントの情報を参照してください
カルタヘナ法
キットコンポーネントの情報を参照してください
Jan Code
キットコンポーネントの情報を参照してください
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
A J Prati et al.
Journal of dental research, 92(12 Suppl), 161S-167S (2013-10-26)
The aim of this study was to compare the release of bone markers during osseointegration of immediately loaded and nonloaded implants. Forty patients who were indicated for rehabilitation with dental implants randomly received either implant and prosthesis placement within 72
Effect of different exercise modalities plus a hypocaloric diet on inflammation markers in overweight patients: a randomised trial.
Loria-Kohen, V; Fernandez-Fernandez, C; Bermejo, LM; Morencos, E; Romero-Moraleda et al.
Clinical Nutrition (Edinburgh, Scotland) null
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.
Pils, D; Tong, D; Hager, G; Obermayr, E; Aust, S; Heinze, G; Kohl, M; Schuster, E; Wolf et al.
BMC Cancer null
Daniel Ajona et al.
Translational research : the journal of laboratory and clinical medicine, 233, 77-91 (2021-02-23)
Lung cancer screening detects early-stage cancers, but also a large number of benign nodules. Molecular markers can help in the lung cancer screening process by refining inclusion criteria or guiding the management of indeterminate pulmonary nodules. In this study, we
Chen-Tzu Chiu et al.
Cancers, 12(6) (2020-06-18)
Head and neck cancer (HNC) accounts for more than 330,000 cancer deaths annually worldwide. Despite late diagnosis being a major factor contributing to HNC mortality, no satisfactory biomarkers exist for early disease detection. Cytoplasmic gelsolin (cGSN) was discovered to predict
関連コンテンツ
MILLIPLEX® マルチプレックスがんアッセイでがんバイオマーカーを検出することにより、腫瘍形成プロセスの研究が加速し、がん研究の進展に役立ちます。
Cancer biomarker detection through MILLIPLEX® multiplex cancer assays can accelerate studies of tumorigenic processes helping advance cancer research.
Learn how multiplexing with MILLIPLEX® multiplex assays can help simplify cancer research by measuring multiple circulating biomarkers at once. Find multiplex panels to analyze JAK-STAT, mTOR, MAPK, SAPK, TGFβ signaling pathways, and more.
MILLPLEXマルチプレックスアッセイで複数の血中バイオマーカーを一度に測定することにより、がん研究を容易にする方法をご覧ください。JAK-STAT、mTOR、MAPK、SAPK、TGFβシグナル伝達経路などを解析するためのマルチプレックスパネルを検索してください。
アクティブなフィルタ
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）
